| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Aquestive Therapeutics, Inc.
13G/A
AQST · 03843E104
|
0.6% |
10/7/2026
Event 10/7/2026
|
||||
| Bratton Douglas K | 0.6% | |||||
| MonoLine RX II, L.P. | 0% | |||||
| MonoLine RX III, L.P. | 0% | |||||
| MonoLine RX, L.P. | 0% | |||||
| MonoLine Partners, L.P. | 0% | |||||
| MonoSol Rx Genpar, L.P. | 0% | |||||
| Bratton Capital Management, L.P. | 0.3% | |||||
| Bratton Capital Inc. | 0.3% | |||||
| Bratton Family Partners L.P. | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.